Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
Status:
RECRUITING
Trial end date:
2027-09-01
Target enrollment:
Participant gender:
Summary
CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.
Phase:
PHASE4
Details
Lead Sponsor:
Henry M. Jackson Foundation for the Advancement of Military Medicine
Collaborators:
Centers for Disease Control and Prevention U.S. Food and Drug Administration (FDA)